McKesson (MCK), a leading global healthcare company and pharmaceutical distributor, is highlighted as a top growth stock, underpinned by its strong performance in specialty pharmaceuticals, oncology, and GLP-1 medications, which generated nearly $41 billion in FY25 revenues. The company holds a Zacks #2 (Buy) Rank, an 'A' VGM Score, and an 'A' Growth Style Score, with analysts forecasting 15.6% year-over-year earnings growth for the current fiscal year. Six analysts recently raised FY26 earnings estimates, increasing the Zacks Consensus Estimate to $38.19 per share, complemented by a historical average earnings surprise of +3.5%.
McKesson Corporation (MCK) is highlighted as a top growth stock, underpinned by its Zacks #2 (Buy) Rank, an "A" VGM Score, and an "A" Growth Style Score. As a leading global healthcare company and pharmaceutical distributor, MCK operates across significant segments including U.S. Pharmaceutical, RxTS, Medical-Surgical Solutions, and International. This strong fundamental positioning suggests robust market standing and operational breadth. The company's growth is significantly driven by specialty pharmaceuticals, oncology services, and GLP-1 medications for diabetes and obesity. Notably, GLP-1 revenues alone contributed nearly $41 billion in fiscal year 2025, indicating a substantial and expanding revenue stream from these high-growth areas. MCK's earnings outlook is positive, with a forecasted year-over-year earnings growth of 15.6% for the current fiscal year. Six analysts have recently revised their fiscal 2026 earnings estimates higher, leading to a $0.98 increase in the Zacks Consensus Estimate to $38.19 per share. The company also boasts a consistent average earnings surprise of +3.5%, reflecting strong operational execution relative to expectations.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request a DemoOverall Sentiment
strongly positive
Sentiment Score
0.85
Ticker Sentiment
